Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

If ingenuity was a person, I'm sure she'd be South African. South Africans have been finding alternate ways of getting things done regardless of what obstacles come our way. Load shedding? We'll ...

After working in the electrical construction trade for more than 30 years, Kyle Falvey decided that it was time to go into ...

Help your organization thrive with an enterprise resource planning (ERP) solution that’s built for growth, optimized for performance, and enhanced with actionable insights delivered through autonomous ...